Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · May 03, 2022

Ribociclib for Treating HR-Positive, HER2-Negative Early and Advanced Breast Cancer

Breast cancer (Dove Medical Press)


Additional Info

Breast cancer (Dove Medical Press)
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
Breast Cancer (Dove Med Press) 2022 Apr 01;14(2022)101-111, MC Parati, R Pedersini, G Perego, R Reduzzi, T Savio, M Cabiddu, K Borgonovo, M Ghilardi, A Luciani, F Petrelli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading